You're contacting media contact of this press release

Title: CoreAge Rx Expands Access to Weight Loss Solutions with Compounded GLP-1 Medications

United States, 20th Nov 2025 — CoreAge Rx, a leading telehealth pharmacy dedicated to providing personalized and accessible medication solutions, today announced the expanded availability of compounded tirzepatide and semaglutide for patients seeking safe and effective weight management options. This development comes at a time of heightened nationwide demand for GLP-1 receptor agonist medications, as many individuals continue to face rising costs and supply shortages of commercially available products.GLP-1 medications—including tirzepatide and semaglutide—have become widely recognized for their clinically significant role in supporting weight reduction, improving metabolic health, and assisting patients with obesity-related concerns. With demand continuing to outpace supply, patients often struggle to obtain timely prescriptions or face prohibitive pricing. CoreAge Rx’s compounded alternatives are designed to bridge this gap by offering a cost-effective and accessible option while maintaining strict quality and safety standards.“Patients deserve dependable access to the treatments that support their long-term health,” said Ella Jones, spokesperson for CoreAge Rx. “By expanding availability of compounded tirzepatide and semaglutide, we are ensuring that people who rely on these medications are not left behind during ongoing shortages. Our mission is to make advanced weight management solutions more affordable and more attainable for patients across the United States.”As a telehealth-focused pharmacy, CoreAge Rx integrates virtual consultations, secure prescriptions, and home delivery to streamline the patient experience from start to finish. The addition of compounded GLP-1 medications further enhances its commitment to offering transparent, personalized, and...

This press release is issued by King Newswire